MAPT and Alzheimer disease: According to the 2024 Alzheimer's Association (AA) Workgroup's diagnostic criteria,1 detection of an abnormal Core 1 biomarker using an accurate BBM assay (specifically phosphorylated tau‐217 [p‐tau217] or the hybrid ratio p‐tau217/np‐tau217, represented as %p‐tau217) is sufficient to establish a diagnosis of AD and inform clinical decision‐making throughout the disease continuum.